WuXi Biologics (Cayman) Inc. (BKK:WUXI06)
4.000
+0.140 (3.63%)
At close: Feb 10, 2026
WuXi Biologics Revenue
WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
7.25
Revenue / Employee
1.60M CNY
Employees
12,552
Market Cap
659.37B THB
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTT PCL | 2.75T |
| CP ALL PCL | 1.02T |
| PTT Exploration and Production PCL | 279.96B |
| Advanced Info Service PCL | 226.26B |
| True Corporation PCL | 201.00B |
| Kasikornbank PCL | 154.49B |
| SCB X PCL | 130.11B |
| Krung Thai Bank PCL | 129.87B |